大摩:降石药集团目标价至6.7港元 评级“增持”

新浪港股
03 Apr
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  摩根士丹利发布研报称,石药集团(01093)去年第四季销售同比升17%,基础利润收窄56%,大致上符合早前公布数据,全年息派0.26港元,派息率达71%。集团提供今年销售及纯利均呈正面增长,主要是新产品贡献能弥补传统药物销售的跌幅。该行指,将集团今年销售预测上调0.5%,维持2026年至2027年销售预测不变,而各三年基础利润预测分别调整为负1%、负3%及负1%。该行将其目标价由6.8港元下调至6.7港元,其评级为“增持”。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10